74 / 464
SATURDAY 6 MAY 2017
74
SCIENTIFIC PROGRAMME
| Programme and Exhibition Guide
JOINT SYMPOSIUM
ESTRO-ASTRO: Cutting edge combined modality therapies (Focus on
NSCLC)
08:45 - 10:00 | AUDITORIUM
Chair: Y. Lievens (Belgium)
Chair: S. Hahn (USA)
08:45 > The gains to be made by combined modality treatment in NSCLC:
setting the scene of new possibilities
Speaker: M. Stuschke (Germany)
SP-0010
09:03 > The use of biomarkers for individualised treatment in NSCLC
Speaker: J. Belderbos (The Netherlands)
SP-0011
09:21 > Abscopal responses in metastatic non-small cell lung cancer (NSCLC):
a phase II study of combined radiotherapy and ipilimumab
Speaker: S. Formenti (USA)
SP-0012
09:39 > The use of novel technologies (e.g. protons) in NSCLC
Speaker: Z. Liao (USA)
SP-0013
SYMPOSIUMWITH PROFFERED PAPERS
Radiotherapy plus immunotherapy combination: rationale and results
so far
08:45 - 10:00 | SCHUBERT
Chair: R. Nout (The Netherlands)
Co-chair: H. Geinitz (Austria)
08:45 >
In situ
Cancer Vaccines: Tumor destruction and immune stimulation for
local and systemic tumor control.
G. Adema (The Netherlands)
SP-0014
09:03 > The impact of tumour infiltrating lymphocytes on clinical outcome after
(chemo)radiotherapy
J. Galon (France)
SP-0015
09:21 > Radiotherapy and immunotherapy combination: paradigm changing or
just hype?
S.J. Dovedi (UK)
SP-0016
09:39 > Combined High Dose Radiation and Ipilimumab in Metastatic
Melanoma, a Phase I Dose Escalation Trial.
K. De Wolf, V. Kruse, L. Brochez, N. Sundahl (Belgium), M. Van Gele,
R. Speeckaert, P. Ost
OC-0017
09:49 > Chemoradiation-induced altered profile of PD-L1 and CD8+ TILs
indicated prognosis in rectal cancer
Y.J. Lim (Republic of Korea), J. Koh, S. Kim, S.R. Jeon, E.K. Chie, K. Kim,
G.H. Kang, S.W. Han, T.Y. Kim, S.Y. Jeong, K.J. Park, H.G. Wu
OC-0018